Results 21 to 30 of about 168,758 (312)

Caveolin-1 protects B6129 mice against Helicobacter pylori gastritis. [PDF]

, 2013
Caveolin-1 (Cav1) is a scaffold protein and pathogen receptor in the mucosa of the gastrointestinal tract. Chronic infection of gastric epithelial cells by Helicobacter pylori (H. pylori) is a major risk factor for human gastric cancer (GC) where Cav1 is
A Bist, A Lee, A Muller, AB Rogers, AS Day, B Razani, C Pelz, C Wunder, CG Hansen, CH Kuo, CH Lai, CH Lai, Christoph Röcken, Claus Schäfer, CM Rosenberger, D Engel, D Forman, D Makola, DW Zaas, E Burgermeister, E Burgermeister, E Burgermeister, E Prade, E Touati, E Touati, Elke Burgermeister, F Lian, F Sommer, FA Medina, FA Medina, FA Medina, Florian Anderl, FS Machado, G Li, G Soong, Gang Yuan, I Mercier, I Regel, IC Arnold, IC Arnold, IC Arnold, IM Toller, Ivana Hitkova, J Li, J Millan, JC Atherton, JE Crabtree, JG Fox, JH Chidlow Jr, JP Boettcher, JS Low, JW Yam, K Ohnuma, K Simons, K Yuan, KM Bourzac, LJ Thompson, M Beigier-Bompadre, M Gadjeva, M Hatakeyama, M Kurayoshi, M Mohammadi, M Yamaga, Markus Gerhard, Matthias P. A. Ebert, MF Dixon, MJ Zhang, ML Hutton, MM D'Elios, MP Ebert, MP Ebert, MR Amieva, NE van Doorn, OA Senkovich, P Gargalovic, P Kundu, P Lajoie, PU Le, R Palovuori, R Rad, R Tsutsumi, Roger Vogelmann, Roland M. Schmid, S Li, S Moese, S Thomas, Simone Reu, Steven R. Blanke, T Kawazoe, T Tomassian, TH Tsai, Thomas Kirchner, TI Jeon, TM Williams, TM Williams, TY Kim, VM Pietiainen, W Schraw, X Cao, X Xing, Y Churin, Y Mitsuno, Y Yamaoka, YC Liao   +103 more
core   +4 more sources

H. pylori and platelet counts [PDF]

Hepatology, 2006
Abstract Helicobacter pylori (HP) eradication therapy is a useful treatment for idiopathic thrombocytopenic purpura (ITP). Some investigators have also reported the effects of proton pump inhibitor (PPI) monotherapy on ITP.
Hays L, Arnold, Stephen A, Harrison
openaire   +2 more sources

Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease : systematic review. [PDF]

, 2003
Objectives: To ascertain the prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease and its association with the disease.
Childs, S., Hungin, A. P. S., Raghunath, A., Wooff, D.   +3 more
core   +2 more sources

Helicobacter pylori virulence factors in duodenal ulceration: A primary cause or a secondary infection causing chronicity [PDF]

, 2006
Reports from countries with a high prevalence of Helicobacter pylori. (H pylori) infection do not show a proportionately high prevalence of duodenal ulceration, suggesting the possibility that H pylori cannot be a primary cause of duodenal ulceration. It
Hobsley, M, Holton, J, Tovey, FI
core   +1 more source

A change of IL-2 and IL-4 production in patients with Helicobactor pylori infection

Mediators of Inflammation, 1995
Helicobactor pylori is the most common cause of gastroduodenal inflammation. However, the exact immune pathogenesis is not fully understood. To look for evidence of the immunological mechanism in H.
X. G. Fan, J. Yakoob, X. J. Fan, P. W. N. Keeling   +3 more
doaj   +1 more source

Helicobacter pylori and Other Gastrointestinal Diseases [PDF]

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2020
Helicobacter pylori (H. pylori) is the most prevalent bacterial pathogen that infects approximately half of the world’s population. It is well known that H. pylori causes chronic gastritis, peptic ulcer, and gastric cancer. H.
Jong Kyu Park
doaj   +1 more source

Prevalence of Helicobacter pylori infection in dyspeptic patients in Iran

Gastroenterology Insights, 2012
Although Helicobacter pylori (H. pylori) infection has been known to be associated with several upper gastrointestinal disorders such as peptic ulcer and gastric cancer, the relationship between H.
Leila Shokrzadeh, Kaveh Baghaei, Yoshio Yamaoka, Seiji Shiota, Dariush Mirsattari, Asma Porhoseingholi, Mohammad Reza Zali   +6 more
doaj   +1 more source

H. pyloriEradication Therapy [PDF]

Gastroenterology Research and Practice, 2013
As a general rule for the treatment of infectious diseases, clinicians should prescribe anti-H. pylori regimens that have a per-protocol eradication rate ≥90%. However, the eradication rate of the standard triple therapy recommended by most guidelines has generally declined to unacceptable levels (i.e., 80% or less) recently.
Ping-I Hsu, Nan-Jing Peng
openaire   +3 more sources

Effect of Helicobacter pylori Eradication on Reflux Esophagitis Therapy: A Multi-center Randomized Control Study

Chinese Medical Journal, 2015
Background: Helicobacter pylori (H. pylori) frequently colonizes the stomach. Gastroesophageal reflux disease (GERD) is a common and costly disease. But the relationship of H. pylori and GERD is still unclear. This study aimed to explore the effect of H.
Yan Xue, Li-Ya Zhou, San-Ren Lin, Xiao-Hua Hou, Zhao-Shen Li, Min-Hu Chen, Xiu-E Yan, Ling-Mei Meng, Jing Zhang, Jing-Jing Lu   +9 more
doaj   +1 more source

A retrospective study assessing the acceleration effect of type I Helicobacter pylori infection on the progress of atrophic gastritis

Scientific Reports, 2021
Based on the antibody typing classification, Helicobacter pylori infection can be divided into type I H. pylori infection and type II H. pylori infection. To observe the effects of different H.
Weidong Liu, Junjie Tian, Wenjia Hui, Wenjie Kong, Yan Feng, Junqiang Si, Feng Gao   +6 more
doaj   +1 more source